Q-omics provides the consensus-scored CPSF1P2 profile across patient tissues and cancer cell-line models. CPSF1P2 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, CPSF1P2 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, CPSF1P2 RNA expression shows 6,460 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUSC, BRCA, and STAD as cancer lineages where CPSF1P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CPSF1P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CPSF1P2 survival associations across molecular data types. CPSF1P2 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CPSF1P2 RNA expression–survival associations across cancer types. High CPSF1P2 expression shows unfavorable associations in LUSC, THYM, THCA, BRCA and OV, but favorable associations in KIRP. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for CPSF1P2 RNA expression.
This table summarizes CPSF1P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CPSF1P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CPSF1P2 shows lower tumor expression in BRCA and higher tumor expression in KIRC. The BRCA box plot shows higher CPSF1P2 RNA expression in normal versus tumor tissue (log2 FC = −0.010, t-test p = .013).
This table shows molecular features associated with CPSF1P2 in patient tissues and cancer cell lines. In patient samples, CPSF1P2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
